Printer Friendly

MAGAININ'S LEAD DRUG CANDIDATE TO ENTER PIVOTAL PHASE IIB/III CLINICAL TRIALS

 PLYMOUTH MEETING, Pa., April 20 /PRNewswire/ -- Magainin Pharmaceuticals Inc. (NASDAQ: MAGN) today announced that MSI-78 was proceeding to pivotal Phase IIB/III clinical trials for the treatment of impetigo, a serious skin infection which usually occurs in children. It is anticipated that this first pivotal clinical trial will commence this summer.
 The decision to proceed was made after reviewing the results of a recently completed Phase II clinical trial with the Food and Drug Administration. MSI-78 is a topically applied broad spectrum antibiotic which exhibits both antibacterial and antifungal activity. In the completed Phase II clinical trial, MSI-78 produced a significant dose and frequency response against a variety of bacteria inoculated on the arms of 45 volunteers. These results are being submitted for presentation at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in the fall.
 In the future, the company intends to test the utility of MSI-78 in a variety of other serious skin infections.
 Magainin Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the research, development and commercialization of anti- infectives and anti-cancer products based upon compounds isolated from the host defense systems of animals.
 -0- 4/20/93
 /CONTACT: Jay Moorin of Magainin Pharmaceuticals Inc., 215-941-4020, or Fern Lazar of Dewe Rogerson, 212-688-6840, for Magainin Pharmaceuticals Inc./
 (MAGN)


CO: Magainin Pharmaceuticals Inc. ST: Pennsylvania IN: MTC SU:

LR-TS -- NY076 -- 8102 04/20/93 13:15 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 20, 1993
Words:231
Previous Article:TAP TO MARKET LUPRON DEPOT-PED AS TREATMENT FOR PRECOCIOUS PUBERTY
Next Article:FITCH AFFIRMS RATINGS ON CFC AND U.S. HOME EQUITY LOAN TRUSTS -- FITCH FINANCIAL WIRE --
Topics:


Related Articles
Magainin Announces Successful MSI-78 Phase III Trial Results
Magainin Announces Successful Results of Second Pivotal Trial For Cytolex (MSI-78)
Trubion Announces Initiation of Phase IIb Clinical Trial of TRU-015 for the Treatment of Rheumatoid Arthritis.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters